[go: up one dir, main page]

PE20180023A1 - Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona - Google Patents

Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona

Info

Publication number
PE20180023A1
PE20180023A1 PE2016000848A PE2016000848A PE20180023A1 PE 20180023 A1 PE20180023 A1 PE 20180023A1 PE 2016000848 A PE2016000848 A PE 2016000848A PE 2016000848 A PE2016000848 A PE 2016000848A PE 20180023 A1 PE20180023 A1 PE 20180023A1
Authority
PE
Peru
Prior art keywords
treatment
hsdd
trazodone
bupropion
women
Prior art date
Application number
PE2016000848A
Other languages
English (en)
Inventor
Nick G Sitchon
Robert E Pyke
Robert Taylor Segraves
Anita Clayton
Leonard Derogatis
Molly Katz
Cindy Meston
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of PE20180023A1 publication Critical patent/PE20180023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a un metodo de tratamiento de una mujer con trastorno del deseo sexual hipoactivo (HSDD) que comprende: a) administracion diaria de un primer farmaco tal como bupropion que tiene una concentracion de dosis de 150 mg; b) administracion diaria de un segundo farmaco tal como trazodona que tiene una concentracion de dosis de 75 mg; y c) dicha administracion del primer y segundo farmaco se encuentra de acuerdo con un regimen de tratamiento prescrito para el tratamiento la mujer para HSDD
PE2016000848A 2016-06-17 2016-06-20 Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona PE20180023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
PE20180023A1 true PE20180023A1 (es) 2018-01-09

Family

ID=57758862

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000848A PE20180023A1 (es) 2016-06-17 2016-06-20 Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona

Country Status (9)

Country Link
KR (1) KR20170142797A (es)
AR (2) AR105087A1 (es)
AU (1) AU2016204151A1 (es)
CA (1) CA2933921A1 (es)
CL (1) CL2016001597A1 (es)
MX (1) MX2016008272A (es)
PE (1) PE20180023A1 (es)
UY (1) UY36742A (es)
WO (1) WO2017218018A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
WO2005102342A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
CN106924259A (zh) * 2012-08-06 2017-07-07 S1制药有限公司 治疗方案

Also Published As

Publication number Publication date
WO2017218018A1 (en) 2017-12-21
MX2016008272A (es) 2017-12-18
UY36742A (es) 2016-12-30
CL2016001597A1 (es) 2017-10-06
CA2933921A1 (en) 2017-12-17
AU2016204151A1 (en) 2018-01-18
KR20170142797A (ko) 2017-12-28
AR105087A1 (es) 2017-09-06
AR105047A1 (es) 2017-08-30

Similar Documents

Publication Publication Date Title
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2021000609A (es) Métodos de tratamiento con fármacos sustrato para cyp3a4.
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
ECSP18024971A (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma
PE20142363A1 (es) Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
MX2017012982A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
CR20170085A (es) Terapia adjuntiva con 25-hidroxi vitamina d
MX2019003134A (es) Terapia de combinacion.
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX373231B (es) Agente anticancerigeno.
MX2018008694A (es) Metodos y composiciones para tratar la hiperhidrosis.
MX2018007933A (es) Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
MX2016014307A (es) Administración asistida de agentes de tratamiento de plantas.
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
CL2017000636A1 (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
PE20180023A1 (es) Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona
EA202091743A1 (ru) Вакцинация дендритными клетками параллельно с химиотерапией